Skip to main content

Table 3 The changes (∆) of clinical parameters from baseline to week 2 in different outcomes and treatment groups

From: On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study

  All Survival Mortality p Telbivudine Entecavir p
Patient no 21 17 4   9 12  
ALT −1161 (−2313-+106) −1161 (−2313-+106) −890 (−2057- -44) 1.000 −1383 (−2313-+106) −547.5 (−2057- -30) 0.256
Bilirubin T −0.4 (−9.1-+12.2) −1.2 (−9.1-+11.5) 8.05 (5.9-12.2) 0.009 −0.9 (−6-+11.5) −0.3 (−9.1-+12.2) 0.722
Creatinine 0.22 (−0.1-+2.33) 0.08 (−0.10-+0.87) 0.49 (0.23-2.33) 0.049 0.22 (−0.09-+0.87) 0.27 (−0.1-+2.33) 0.594
eGFR        
  MDRD −23 (−162-+58) −16 (−72-+58) −85.5 (−162- -36) 0.008 −23 (−99-+23) −23 (−162-+58) 0.749
  CKD-EPI −16.1 (−65.2-+12.6) −6.0 (−65.2-+12.6) −35.5 (−51.3- -21.7) 0.049 −21.1 (−65.2-+6.81) −13.0 (−51.3-+12.6) 0.776
INR −0.3 (−1.0-+0.9) −0.3 (−1.0-+0.9) −0.4 (−0.5-+0.7) 0.318 −0.3 (−0.6-+0.9) −0.3 (−1.0-+0.7) 0.971
AFP 151.5 (−140.7-+2326.6) 184.2 (−110.2-+2326.6) −73.2 (−140.7- -5.8) 0.057 184.2 (−5.8-+1385.9) 101.2 (−140.7-+2326.6) 0.386
HBV DNA (log10 cps/ml) −3.27 (−5.47- -0.55) −3.4 (−5.5- -0.6) −1.4 (−1.8- -1.0) 0.074 −3.4 (−5.0- -1.0) −3.0 (−5.5- -0.6) 0.922
MELD score −1.0 (−11-+14) −1.0 (−11-+14) 0.0 (−1-+12) 0.344 −1.0 (−6-+14) −0.5 (−11-+12) 0.775
  1. Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m2), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m2), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.